Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MoneyHero

    MCap

    USD60m

    Last close

    USD2.35

    ▲ 0.55 (30.56%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sareum Holdings (AIM: SAR)

Last close As at 25/04/2024

GBP0.26

▲ −4.25 (−13.93%)

Market capitalisation

GBP28m

Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its pre-clinical TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is undergoing advanced dose finding and toxicology studies with a target to file a CTA in mid-2021. Other programmes include the CHK1 inhibitor SRA737 (Sareum holds a 27.5% economic interest), previously out licensed to Sierra Oncology and the de-prioritised FLT3+Aurora kinase.

Latest Insights

View More

Healthcare | Update

Sareum Holdings — A decisive period ahead for SDC-1801

Healthcare | Flash note

Sareum Holdings — Positive clinical step forward in SDC-1801

Healthcare | Flash note

Sareum Holdings — SRA737 – new partnership to kick off the year

Healthcare | Update

Sareum Holdings — SDC-1801 embarks on clinical journey in FY23
Sareum Holdings_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Key Management

  • John Reader

    CSO

  • Stephen Parker

    Chairman

  • Tim Mitchell

    CEO

Balance Sheet

Forecast net cash (£m)

0.5

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 87.5 (47.5) (74.4)
Relative 84.3 (50.7) (75.0)
52 week high/low 142.5p/10.2p

Financials

Sareum Holdings’ H124 results highlighted the company’s swift progress for lead asset SDC-1801, since gaining regulatory approval in Australia to start human studies in mid-CY23. SDC-1801, a TYK2/JAK1 inhibitor targeting the autoimmune space, has reported a good safety profile to date and top-line data for the ongoing Phase Ia study are expected in Q2 CY24, a key catalyst for the company. The TYK2 class’s safety and efficacy has been validated by the likes of Sotyktu and TAK-279, and SDC-1801’s dual inhibition may provide differentiation, in our opinion. Funding, however, remains an overhang (period-end cash of £0.4m; operating loss of c £2.5m in H124) and will likely dictate the timing/pace of the Phase IIa study in psoriasis patients, currently planned for end-CY24. We expect the recent £2.3m capital raise and upcoming tax credits (£0.7m) to offer some headroom but anticipate the need for further funds in CY24.

Research

Flash note

Healthcare

Sareum Holdings — SDC-1801 CTA application hits a roadblock

Update

Sareum Holdings — SDC-1801 poised for the clinic

Healthcare

Flash note

Sareum Holdings — SDC-1801 trial application refiled in Australia

Flash note

Sareum Holdings — Sierra Oncology returns rights to SRA737

Flash note

Healthcare

Sareum Holdings — Sotyktu approval positive read-across for SDC-1801

Flash note

Healthcare

Sareum Holdings — SDC-1801 CTA filed in the UK

Flash note

Healthcare

Sareum Holdings — GSK’s Sierra acquisition, read-across for Sareum

Update

Healthcare

Sareum Holdings — Approaching the clinic

edison tv

Healthcare

Sareum Holdings: Edison Open House Healthcare 2022

Flash note

Healthcare

Sareum Holdings — AGM produces key highlights

Update

Healthcare

Sareum Holdings — SDC-1801’s clinical plan modified

Flash note

Healthcare

Sareum Holdings — Fund raising to cushion pipeline risk

edison tv

Healthcare

Sareum Holdings – Edison Open House interview

Initiation

Healthcare

Sareum Holdings — Treading the TYK2 trail

QuickView

Healthcare

Sareum Holdings — Starting to tick the right boxes